Convertibles Calendar: Medicines to price $300 million; Resource Capital on tap

January 7

MEDICINES CO.:

• $300 million convertible senior notes

• Maturity 2022

• Rule 144A

• Non-callable for life

• Joint bookrunners Goldman Sachs & Co., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC

• Parsippany, N.J.-based developer of products that improve specialized care

• Nasdaq: MDCO

RESOURCE CAPITAL CORP.:

• $100 million convertible senior notes

• Maturity 2020

• Registered

• Non-callable for life

• Takeover and dividend protection

• Joint bookrunners Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC

• Co-managers Keefe Bruyette & Woods Inc., JMP Securities LLC and MLV & Co LLC

• Proceeds for general corporate purposes, including acquisitions, loan originations and working capital

• New York-based specialty finance company focused on commercial loans

• NYSE: RSO

On The Horizon

INOTEK PHARMACEUTICALS CORP.:

• Convertible senior notes

• Maturity 2019

• Concurrent initial public offering of common stock

• Registered

• Non-callable for life

• Takeover and dividend protection

• Joint bookrunners Cowen & Co. LLC, Piper Jaffray & Co., Canaccord Genuity Inc. and Nomura Securities International Inc.

• Proceeds to fund the continued development of its pharmaceutical candidates and for other general corporate purposes, including repayment of borrowings under and the termination of existing notes payable agreements

• Beverly, Mass.-based development-stage pharmaceutical company

• Proposed Nasdaq listing: ITEK

CARNIVAL GROUP INTERNATIONAL HOLDING LTD.:

• Unsecured senior convertible bonds

• Bookrunner Deutsche Bank AG, Hong Kong Branch

• Regulation S

• Concurrent equity swap with Deutsche Bank AG, London Branch as equity swap counterparty

• Proceeds to fund existing and new projects; entry into the equity swap; and for working capital and other general corporate purposes

• Bermuda-based investment holding company engaged in leisure and consumption businesses

• Hong Kong: 00996

PLATFORM SPECIALTY PRODUCTS CORP.:

• Convertible securities as part of a funding package of cash, convertibles, debt and equity

• Proceeds to fund $3.51 billion acquisition of Arysta LifeScience Ltd., a Tokyo-based provider of agrochemical and biological products

• Barclays, Credit Suisse Securities (USA) LLC, Nomura Securities International LLC and UBS AG acted as M&A advisers and have committed financing for the acquisition

• Anticipated closing in first quarter 2015

• Miami-based specialty chemicals company

• NYSE: PAH

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.